FAQ: Annovis Bio's $3.4 Million Registered Direct Offering

What is the main announcement in this content?

Annovis Bio Inc. has entered definitive agreements for a registered direct offering of 1,670,732 shares of common stock at $2.05 per share, raising approximately $3.4 million.

How much money is Annovis Bio raising through this offering?

The company is raising $3.4 million through the sale of 1,670,732 shares at $2.05 per share, which reflects the October 24 closing price.

Who is involved in this offering?

The offering is led by H.C. Wainwright & Co. as exclusive placement agent, with participation from Chairman Michael Hoffman and CEO Dr. Maria Maccecchini.

When is the offering expected to close?

The closing is expected on or about October 28, 2025.

What will the proceeds from this offering be used for?

The proceeds are earmarked for working capital and general corporate purposes to support the company’s operations and development activities.

What type of company is Annovis Bio?

Annovis Bio is a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s disease.

Where is Annovis Bio headquartered?

The company is headquartered in Malvern, Pennsylvania.

Where can investors find more information about Annovis Bio?

Investors can visit the company’s website at www.annovisbio.com, follow them on LinkedIn, YouTube, and X, or access the latest news at https://ibn.fm/ANVS.

Why is this offering significant for Annovis Bio?

This funding provides essential capital for the company’s working capital needs, supporting their ongoing development of innovative therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s.

What is the role of H.C. Wainwright & Co. in this offering?

H.C. Wainwright & Co. is serving as the exclusive placement agent for the registered direct offering, facilitating the transaction and sale of shares to investors.